Global Buccal Drug Delivery System market share 2024, Forecast To 2033
29 Feb, 2024
The buccal drug delivery system market has experienced rapid growth in recent years, escalating from$3.28 billion in 2023 to$3.64 billion in 2024, reflecting a notable compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to early innovations in drug delivery, widespread adoption within the pharmaceutical industry, extensive clinical studies validating efficacy, and targeted market penetration strategies, particularly in disease-specific applications. Looking forward, the market is poised for continued expansion, with projections indicating a rise to$5.43 billion by 2028, driven by patient-centric drug delivery approaches, a burgeoning geriatric population, increased demand for targeted therapies including biologics and peptides, supportive regulatory frameworks, and amplified investments in research and development. Major trends in the forecast period encompass enhancing patient convenience and compliance, advancements in drug formulations to improve bioavailability, the escalating prevalence of chronic diseases necessitating sophisticated drug delivery mechanisms, and heightened focus on pediatric and geriatric care.
Global Buccal Drug Delivery System Market Key Driver
The rising prevalence of chronic diseases is expected to propel the growth of the buccal drug delivery systems market going forward. Chronic diseases refer to ailments that persist for a year or longer, such as cancer, heart disease, stroke, diabetes, cancer, and arthritis. These are the most prevalent chronic illnesses that can be managed but not cured and necessitate continuous nutrition and medical care. Buccal drug delivery systems provide appropriate and effective drug delivery for administering mucosal and transmucosal drugs that are required by several patients suffering from chronic diseases such as diabetes and cancer. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. There were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Therefore, the rising prevalence of chronic diseases drives the growth of the buccal drug delivery systems market. In 2023, the buccal drug delivery systems market was valued at $6.2 billion, and it is expected to grow to $10.8 billion by 2028.
Get A Free Sample Of The Global Buccal Drug Delivery System Market ReportGlobal Buccal Drug Delivery System Market Segments
The global buccal drug delivery system market covered in this report is segmented –
1) By Type: Sublingual, Buccal Tablets and Lozenges, Oral Sprays
2) By Application: Pain Management, Smoking Cesstion, Angina Pectoris
3) By End-User: Hospitals, Ambulatory Centers, Other End-Users
By Geography: The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa.
North America was the largest region in the buccal drug delivery systems market share in 2023. The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Buccal Drug Delivery System Industry Players
Teva Pharmaceuticals Industries Ltd., Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc., Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd., AstraZeneca PLC, F Hoffmann-La Roche Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Novo Nordisk A/S, Ethypharm SAS, Applied Pharma Research SA, Sunovion Pharmaceuticals Inc., Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc., NAPP Pharmaceutical Ltd., Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc., Par Pharmaceutical Companies Inc., Acorda Therapeutics Inc., Opiant Pharmaceuticals Inc.
Get The Full Global Buccal Drug Delivery System Market Report
Buccal Drug Delivery System Market Overview
The buccal drug delivery system refers to the injection of the desired medicine through the buccal mucosal membrane lining of the mouth cavity. This method is effective for administering mucosal and transmucosal drugs. Mucosal drug delivery aims for site-specific drug release on the mucosa, whereas transmucosal permeation entails drug absorption across the mucosal barrier and into the systemic circulation.
Buccal Drug Delivery System Global Market Report 2023 provides data on the global buccal drug delivery system market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The buccal drug delivery system market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.